Teon Therapeutics Appoints Glen Giovannetti as Independent Board Member
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 12, 2021 /PRNewswire/ Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced the appointment of Glen Giovannetti, to its board of directors. Glen brings over 36 years of leadership success, industry expertise and board governance credentials following his retirement from EY (Ernst & Young) in December 2020. As EY s former Global Biotechnology and Life Sciences Leader, Glen has deep life sciences knowledge and financial governance, risk and reporting expertise. We are excited to have Glen joining our board, said Ken Horne, President and Chief Operating Officer of Teon Therapeutics. His experience as lead partner on numerous IPOs and M&A transactions in the biotech industry will be invaluable f
Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK
News provided by
Share this article
Share this article
SAN FRANCISCO, Dec. 14, 2020 /PRNewswire/ Teon Therapeutics, a private biopharmaceutical company developing a focused portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment, today announced that Cancer Research UK, the world s leading cancer charity dedicated to saving lives, has formally approved Teon s TT-702 program to enter into a clinical collaboration. TT-702, a first-in-class A
2BR-specific antagonist being pursued in prostate cancer and other tumor types, expects to initiate a Phase 1b/2a clinical study in early 2021. In a collaboration, Cancer Research UK would sponsor and oversee the clinical trial, which will be run through the Centre for Drug Development. Future considerations would be contingent upon achievement of TT-702 development milestones by Teon.